Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 415

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 415
---
 Total | Non-current 
        2025 |  2026 |  2027 |  2028 |  2029 |
|:-------------------------------------------------------------------------------|------------:|--------:|------------:|------:|------:|------:|------:|
| Bond issues                                                                    |      14,592 |   2,716 |       3,010 | 1,150 | 1,666 | 1,300 | 4,750 |
| Other bank borrowings                                                          |       1,354 |   1,290 |          32 |     1 |     1 |     1 |    29 |
| Other borrowings                                                               |           3 |       3 |           — |     — |     — |     — |     — |
| Bank credit balances                                                           |         209 |     209 |           — |     — |     — |     — |     — |
| Interest rate and currency derivatives usedto manage debt                      |          13 |      13 |           — |     — |     — |     — |     — |
| Total debt                                                                     |      16,171 |   4,231 |       3,042 | 1,151 | 1,667 | 1,301 | 4,779 |
| Cash and cash equivalents                                                      |      -7,441 |  -7,441 |           — |     — |     — |     — |     — |
| Interest rate and currency derivatives usedto manage cash and cash equivalents |          76 |      76 |           — |     — |     — |     — |     — |
| Net debt(a)                                                                    |       8,806 |  -3,134 |       3,042 | 1,151 | 1,667 | 1,301 | 4,779 |

(a) Net debt does not include lease liabilities, which amounted to € 1,906 million as of December 31, 2024; € 2,030 million as of December 31, 2023;

and € 2,181 million as of December 31, 2022 (see the maturity analysis at Note D.17.2.).

As of December 31, 2024 , the main undrawn confirmed general-purpose credit facilities at holding company level amounted

to € 8billion , half of which expired in 2027 and the other half of which expires in